Table 2.
Hospitalization treatments, events, and outcomes in the AHA COVID-19 registry
| NHW | AAPIa | Chinese | Asian Indian | Pacific Islander | Vietnamese | Hispanicb | Mexican | Puerto Rican | |
| N | 7926 | 902 | 149 | 77 | 74 | 61 | 4683 | 681 | 46 |
| Treatments during hospitalization | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ICU admission | 2646 (33%) | 285 (32%) | 48 (32%) | 23 (30%) | 16 (22%) | 21 (34%) | 1249 (27%) | 170 (25%) | 7 (15%) |
| Mechanical ventilation | 1444 (18%) | 191 (21%) | 40 (27%) | 19 (25%) | 7 (10%) | 13 (21%) | 889 (19%) | 114 (17%) | 7 (15%) |
| New RRT | 248 (3%) | 36 (4%) | 12 (8%) | 1 (1%) | 4 (5%) | 2 (3%) | 159 (3%) | 13 (2%) | 3 (7%) |
| Transfusion | 255 (3%) | 30 (3%) | 8 (5%) | 5 (6%) | 3 (4%) | 5 (8%) | 128 (3%) | 10 (2%) | 1 (2%) |
| Hydroxychloroquine | 2196 (28%) | 354 (39%) | 86 (58%) | 32 (42%) | 9 (12%) | 15 (25%) | 1952 (42%) | 291 (43%) | 12 (26%) |
| Remdesivir | 1483 (19%) | 138 (15%) | 4 (3%) | 10 (13%) | 22 (30%) | 15 (25%) | 648 (14%) | 90 (13%) | 8 (17%) |
| Tocilizumab | 554 (7%) | 84 (9%) | 10 (7%) | 11 (14%) | 3 (4%) | 10 (16%) | 432 (9%) | 60 (9%) | 3 (7%) |
| Steroids | 3122 (39%) | 286 (32%) | 29 (20%) | 21 (27%) | 24 (46%) | 30 (49%) | 1463 (31%) | 140 (21%) | 9 (20%) |
| Convalescent serum | 751 (10%) | 51 (6%) | 1 (1%) | 7 (9%) | 6 (8%) | 7 (12%) | 292 (6%) | 55 (8%) | 2 (4%) |
| Hospitalization events and outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| In-hospital mortality | 1294 (16%) | 146 (16%) | 42 (28%) | 11 (14%) | 4 (5%) | 9 (15%) | 628 (13%) | 123 (18%) | 6 (13%) |
| Age at death, mean (SD) |
75.7 (13.5) |
75.0 (12.9) |
76.0 (12.1) | 72.1 (13.1) | 61.5 (19.8) | 78.6 (10.3) |
67.3 (15.5) |
67.7 (15.5) |
78.5 (6.5) |
| YPLL per death, mean (SD)c |
10.8 (11.7) |
11.0 (11.7) |
10.1 (10.7) | 14.2 (10.9) | 24.5 (17.9) | 8.4 (7.5) |
18.3 (14.6) |
18.0 (14.6) |
7.0 (5.7) |
| MACE | 1628 (21%) | 180 (20%) | 50 (34%) | 17 (22%) | 6 (8%) | 12 (20%) | 727 (15%) | 150 (22%) | 7 (15%) |
| Heart failure | 158 (2%) | 16 (2%) | 2 (1%) | 3 (4%) | 2 (3%) | 2 (3%) | 58 (1%) | 19 (3%) | 0 (0%) |
| Stroke | 124 (2%) | 17 (2%) | 4 (3%) | 2 (3%) | 0 (0%) | 2 (3%) | 42 (1%) | 4 (1%) | 0 (0%) |
| MI | 282 (4%) | 28 (3%) | 9 (6%) | 2 (3%) | 3 (4%) | 2 (3%) | 75 (2%) | 16 (2%) | 2 (4%) |
| Cardiac arrest | 280 (4%) | 21 (4%) | 11 (7%) | 4 (5%) | 1 (1%) | 1 (2%) | 274 (6%) | 55 (8%) | 2 (4%) |
| Length of stay, days, mean (SD) | 10 (11) | 10 (11) | 11 (11) | 10 (20) | 11 (13) | 10 (10) | 10 (12) | 9 (10) | 10 (10) |
AAPI: Asian American/Pacific Islander, MCS: mechanical circulatory support, MI: myocardial infarction, NHW: non-Hispanic White, RRT: renal replacement therapy, YPLL: years of potential life lost. Data are presented as frequency (percentage) unless otherwise specified. aAAPI includes Chinese, Indian, Pacific Islander, Vietnamese, and other Asian participants either not further specified or in groups too small to analyze separately. bHispanic includes Mexican, Puerto Rican, and other Hispanic participants either not further specified or in groups too small to analyze separately. cYPLL per death indicates mean number of years of potential life lost from age 85 among decedents in each subgroup.